Not Condition-specificNCT02908893
Promoting Flu Vaccination Through a Mobile Wellness Program
A study testing In-app and push notification mobile messages in people with Not Condition-specific, run by Evidation Health at 1 site in United States.
Trial summary
The investigators design a 6-week messaging campaign aimed at promoting flu vaccination among fully insured members of a national payer that participate in a wellness program offered by the insurer through a mobile app. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Not Condition-specific
- What is being tested?
- In-app and push notification mobile messages
- Type of treatment
- Vaccines, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50,286 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2016to Jun 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- belongs to fully insured population
- continuous health coverage between January 1, 2015 and June 1, 2016
- has downloaded and installed the wellness platform app
Who cannot join
- has declined the messaging from the platform
Trial locations and contacts
1 site in 1 country.
About this study
The investigators design a 6-week messaging campaign aimed at promoting flu vaccination among fully insured members of a national payer that participate in a wellness program offered by the insurer through a mobile app. Outcomes measured will include uptake in flu vaccination rate as measured by the insurer and engagement with the campaign through the app.
The goal of the research is to assess the effectiveness of pervasive computing messaging in promoting preventative care treatments such as flu shots. An additional goal is that of quantifying the importance of emphasizing incentives to increase efficacy of the messages.
- Conditions
- Not Condition-specific
- Being tested
- In-app and push notification mobile messages
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
In-app and push notification mobile messagesBehavioural
Short messages (100-250 characters) are to be delivered to a mobile app both by push notification (i.e., appearing on the phone dashboard like a text message if the user has allowed notifications from the app) and in-app messages (visible in the news feed of the wellness program app when the app is opened). Messages contain a short title (30 characters) and 2-3 lines of text in the body (30 characters each).
| Study group | Role | What they receive |
|---|---|---|
| Salient | Experimental | Messages in the salient arm highlight the number of incentives (points) received by getting a flu shot and recording it through the wellness program app.
Additionally, messages mention that flu shots can be received at the pharmacy while picking up an Rx.
Users in the arm are matched up with a second user from the same arm, randomly. For each pair, the messages are sent to both users at the same time within the specified time window. Such time is picked to be the day in which the first user is most likely to pick up an Rx from a pharmacy. Receives: Behavioral: In-app and push notification mobile messages |
| NonSalient | Active comparator | Messages in the non-salient arm highlight the benefits of getting vaccinated against flu, but make no mention of incentives received for getting vaccinated.
Incentives would still be earned through the wellness program if the vaccination is recorded. Messages mention that flu shots can be received at the pharmacy while picking up an Rx.
Users in the arm are matched up with a second user from the same arm, randomly. For each pair, the messages are sent to both users at the same time within the specified time window. Such time is picked to be the day in which the first user is most likely to pick up an Rx from a pharmacy Receives: Behavioral: In-app and push notification mobile messages |
| Control | No intervention | Users in this group will not receive any message promoting flu vaccination. Incentives would still be earned through the wellness program if the vaccination is recorded. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Increase in vaccination rate vs control
Increase in vaccination rate of anyone messaged relative to the control condition
Measured: Up to 1 week after the end of each of the three batches of the intervention (Oct 1/15/28 2016)
Increase in vaccination rate of salient vs non-salient
Increase in vaccination rate of those who received salient incentives messages vs those who received generic messages
Measured: Up to 1 week after the end of each of the three batches of the intervention (Oct 1/15/28 2016)
Secondary outcomes (4)
Decrease in medically attended flu events of messaged vs control
Decrease in observed flu rate for messaged users
Measured: Up to 1 week after the end of each of the three batches of the intervention (Oct 1/15/28 2016)
Increase in reporting of flu vaccination through wellness app of salient vs non-salient
Increase in reporting vaccination through the wellness program app following messages
Measured: Up to 1 week after the end of each of the three batches of the intervention (Oct 1/15/28 2016)
Increase in vaccination rate for users messaged within 2 days before of an expected rx pick-up.
Increase in vaccination rate of users messaged within 2 days before an expected Rx pick up from a pharmacy relative to their paired partners.
Measured: Up to 1 week after the end of each of the three batches of the intervention (Oct 1/15/28 2016)
Increase in message open rate of Salient vs Non-salient arm
Increase in open rate of sent messages through the wellness program app of salient vs non salient arm
Measured: Up to 1 week after the end of each of the three batches of the intervention (Oct 1/15/28 2016)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Sep 2016 (estimated)
- Study startSep 2016
- Primary completionDec 2016
- Study completionJun 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Not Condition-specificStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 50,286 participants (actual)
Sponsor and investigators
- Lead sponsor
- Evidation Health
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Defense Advanced Research Projects Agency, Army Research Laboratory
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02908893
- Sponsor's protocol ID
- EH-002
- Status last verified
- Sep 2026
- First submitted
- 9 Sep 2016
- Last updated
- 18 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided: Aggregated outcome data may be shared.
Publications
Lee WN, Stuck D, Konty K, Rivers C, Brown CR, Zbikowski SM, Foschini L. Large-scale influenza vaccination promotion on a mobile app platform: A randomized controlled trial. Vaccine. 2020 Apr 16;38(18):3508-3514. doi: 10.1016/j.vaccine.2019.11.053. Epub 2019 Nov 29.
PubMed 31787410
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Promoting Flu Vaccination Through a Mobile Wellness Program
- ClinicalTrials.gov ID
- NCT02908893
- Acronym / sponsor ID
- EH-002
- Conditions
- Not Condition-specific
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50,286 participants (actual)
- Lead sponsor
- Evidation HealthIndustry (pharma, biotech, devices)
- Collaborators
- Defense Advanced Research Projects Agency, Army Research Laboratory
- Study start
- Sep 2016 (actual)
- Primary completion
- Dec 2016 (actual)
- Study completion
- Jun 2017 (actual)
- First posted
- 21 Sep 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators design a 6-week messaging campaign aimed at promoting flu vaccination among fully insured members of a national payer that participate in a wellness program offered by the insurer through a mobile app. Outcomes measured will include uptake in flu vaccination rate as measured by the insurer and engagement with the campaign through the app.
The goal of the research is to assess the effectiveness of pervasive computing messaging in promoting preventative care treatments such as flu shots. An additional goal is that of quantifying the importance of emphasizing incentives to increase efficacy of the messages.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Salient | Experimental | Behavioral: In-app and push notification mobile messagesMessages in the salient arm highlight the number of incentives (points) received by getting a flu shot and recording it through the wellness program app. Additionally, messages mention that flu shots can be received at the pharmacy while picking up an Rx. Users in the arm are matched up with a second user from the same arm, randomly. For each pair, the messages are sent to both users at the same time within the specified time window. Such time is picked to be the day in which the first user is most likely to pick up an Rx from a pharmacy. |
| NonSalient | Active comparator | Behavioral: In-app and push notification mobile messagesMessages in the non-salient arm highlight the benefits of getting vaccinated against flu, but make no mention of incentives received for getting vaccinated. Incentives would still be earned through the wellness program if the vaccination is recorded. Messages mention that flu shots can be received at the pharmacy while picking up an Rx. Users in the arm are matched up with a second user from the same arm, randomly. For each pair, the messages are sent to both users at the same time within the specified time window. Such time is picked to be the day in which the first user is most likely to pick up an Rx from a pharmacy |
| Control | No intervention | –Users in this group will not receive any message promoting flu vaccination. Incentives would still be earned through the wellness program if the vaccination is recorded. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- belongs to fully insured population
- continuous health coverage between January 1, 2015 and June 1, 2016
- has downloaded and installed the wellness platform app
Key exclusion criteria (1 listed)
- has declined the messaging from the platform
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| In-app and push notification mobile messagesShort messages (100-250 characters) are to be delivered to a mobile app both by push notification (i.e., appearing on the phone dashboard like a text message if the user has allowed notifications from the app) and in-app messages (visible in the news feed of the wellness program app when the app is opened). Messages contain a short title (30 characters) and 2-3 lines of text in the body (30 characters each). | Behavioural | NonSalient, Salient |
Primary outcome
Increase in vaccination rate vs control
Time frame: Up to 1 week after the end of each of the three batches of the intervention (Oct 1/15/28 2016)
Increase in vaccination rate of anyone messaged relative to the control condition
Increase in vaccination rate of salient vs non-salient
Time frame: Up to 1 week after the end of each of the three batches of the intervention (Oct 1/15/28 2016)
Increase in vaccination rate of those who received salient incentives messages vs those who received generic messages
4 secondary outcomes
Decrease in medically attended flu events of messaged vs control
Time frame: Up to 1 week after the end of each of the three batches of the intervention (Oct 1/15/28 2016)
Increase in reporting of flu vaccination through wellness app of salient vs non-salient
Time frame: Up to 1 week after the end of each of the three batches of the intervention (Oct 1/15/28 2016)
Increase in vaccination rate for users messaged within 2 days before of an expected rx pick-up.
Time frame: Up to 1 week after the end of each of the three batches of the intervention (Oct 1/15/28 2016)
Increase in message open rate of Salient vs Non-salient arm
Time frame: Up to 1 week after the end of each of the three batches of the intervention (Oct 1/15/28 2016)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2026.
- Derived from this study: PubMed 31787410Lee WN, Stuck D, Konty K, Rivers C, Brown CR, Zbikowski SM, Foschini L. Large-scale influenza vaccination promotion on a mobile app platform: A randomized controlled trial. Vaccine. 2020 Apr 16;38(18):3508-3514. doi: 10.1016/j.vaccine.2019.11.053. Epub 2019 Nov 29.
- Individual participant dataSharing planned: Undecided. Aggregated outcome data may be shared.
Related trials for Not Condition-specific
RecruitingPhase 2
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm
Active, not recruitingPhase 2/3
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma
Active, not recruitingPhase 1
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia
RecruitingPhase 1
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma
Active, not recruitingPhase 2
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing In-app and push notification mobile messages in people with Not Condition-specific, run by Evidation Health at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Increase in vaccination rate vs control (time frame: Up to 1 week after the end of each of the three batches of the intervention (Oct 1/15/28 2016)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02908893, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2026.